Charles Zhu
Stock Analyst at LifeSci Capital
(2.49)
# 2,123
Out of 4,829 analysts
24
Total ratings
47.62%
Success rate
13.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $1.35 | - | 1 | Dec 13, 2024 | |
| TNGX Tango Therapeutics | Maintains: Buy | $18 → $8 | $1.14 | +601.75% | 3 | Nov 7, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.43 | +739.16% | 4 | Nov 7, 2023 | |
| MRUS Merus | Maintains: Buy | $46 → $48 | $40.90 | +17.36% | 6 | Aug 8, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $69.85 | -19.83% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $3.24 | +579.01% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $4.81 | +440.54% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $17.42 | +83.70% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $11.31 | +23.84% | 2 | May 5, 2022 |
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.35
Upside: -
Tango Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $18 → $8
Current: $1.14
Upside: +601.75%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.43
Upside: +739.16%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $40.90
Upside: +17.36%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $69.85
Upside: -19.83%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $3.24
Upside: +579.01%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $4.81
Upside: +440.54%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $17.42
Upside: +83.70%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $11.31
Upside: +23.84%